TEANECK, N.J. — In the landscape of American philanthropy and specialized healthcare support, few stories are as poignant or as transformative as that of Sharsheret. This year marks a somber yet celebratory milestone: the 10th anniversary of the passing of its founder, Rochelle Shoretz. To commemorate this decade and ensure the organization’s continued vitality, Shoretz’s sons, Shlomo and Dovid Mirsky, have launched a high-profile year-end appeal, urging the community to sustain the "chain" their mother forged while battling stage IV breast cancer.
What began in 2001 as a small gathering of five women around a dining room table has evolved into a national powerhouse that serves more than 275,000 individuals annually. As the organization enters its 2025 year-end giving season, the focus is not merely on reflection, but on the massive expansion of services required to meet the needs of a community still grappling with the disproportionate impact of hereditary breast and ovarian cancer.
Main Facts: A Mission Born of Necessity
The core of the Mirsky brothers’ appeal rests on a simple premise: no one should face a cancer diagnosis alone, particularly when cultural and religious nuances add layers of complexity to the journey. Sharsheret—the Hebrew word for "chain"—was founded by Rochelle Shoretz at the age of 28. A former law clerk to Supreme Court Justice Ruth Bader Ginsburg, Shoretz was a young mother of two when she was diagnosed with breast cancer.
At the time, the intersection of Jewish identity and cancer was rarely discussed openly. Shoretz found that while general support groups existed, they often failed to address the specific concerns of young Jewish women: the impact of chemotherapy on fertility in a culture that prizes large families, the navigation of kosher dietary laws during treatment, and the genetic implications for a community where one in 40 individuals of Ashkenazi descent carries a BRCA gene mutation—ten times the rate of the general population.
Today, Sharsheret provides a suite of 15 national programs. These range from "Thriving Again," which focuses on life after treatment, to "Best Face Forward," which addresses the cosmetic side effects of chemotherapy. The year-end campaign is designed to fund these programs, which are offered free of charge to women and families across the United States.
Chronology: From Silence to Advocacy (2001–2025)
2001: The Diagnosis and the Taboo
When Rochelle Shoretz was diagnosed in 2001, she describes a world of "shame and silence." In many corners of the Jewish community, cancer was a "taboo subject," according to Shlomo and Dovid Mirsky. Shoretz’s search for a peer who understood her specific vantage point led her to Lauryn Weiser, another young Jewish mother. This connection became the blueprint for Sharsheret’s Peer Support Network.
2001–2015: Building the Infrastructure
Throughout her own fluctuating health battles, Shoretz worked tirelessly to institutionalize her vision. She recognized that the "chain" needed to be more than just emotional support; it needed to be a resource for education and genetic awareness. Sharsheret began partnering with major medical centers and the Centers for Disease Control and Prevention (CDC) to raise awareness about the BRCA mutation.
June 2015: A Profound Loss
Rochelle Shoretz passed away at the age of 42 due to complications from breast cancer. Her death sent shockwaves through the non-profit world, but the organization she built was prepared. She had spent years ensuring that Sharsheret was not dependent on her personality alone, but on a robust professional staff and a dedicated board of directors.
2015–2025: Exponential Growth
In the decade since Shoretz’s passing, Sharsheret has expanded its reach from a boutique organization to an international movement. The brothers note that while their mother missed major family milestones—graduations, weddings, and the birth of grandchildren—her "professional child," Sharsheret, has matured into an entity that now touches over a quarter of a million lives every year.
Supporting Data: The Impact of Sharsheret’s Programs
The scale of Sharsheret’s operations in 2025 is backed by significant data regarding the needs of the Jewish community and the efficacy of the organization’s interventions.
The Genetic Landscape
Statistics from the National Cancer Institute confirm that women of Ashkenazi Jewish descent have a significantly higher risk of carrying mutations in the BRCA1 and BRCA2 genes. These mutations carry a lifetime risk of up to 80% for breast cancer and up to 45% for ovarian cancer. Sharsheret’s "Genetics for Life" program has become a primary resource for families navigating these statistics, providing counseling that integrates medical data with Jewish law (Halacha) and family dynamics.
The "Busy Box" and Family Support
One of the most emotional points in the Mirsky brothers’ appeal is the mention of the "Busy Box." This program provides age-appropriate resources and toys for children whose parents are undergoing treatment.
- Family Reach: To date, thousands of Busy Boxes have been shipped to families across the country.
- Psychological Impact: Internal surveys by the organization suggest that these interventions significantly reduce the anxiety levels of children by providing a structured way for parents to discuss their illness.
Annual Reach and Growth
- Individuals Served: 275,000+ annually.
- Webinars and Education: Sharsheret hosts over 100 educational events per year, reaching participants in all 50 states and several countries.
- Peer Support: The organization maintains a database of thousands of "Peer Supporters"—survivors who are matched with the newly diagnosed based on age, diagnosis, and lifestyle.
Official Responses: Continuing the Vision
In their open letter, Shlomo and Dovid Mirsky emphasize that the organization’s success is a testament to the community’s generosity. "What started as five women around our dining room table has turned into an international movement," they wrote. "We know that thanks to your generosity, Mom is looking down with pride as we build a healthier and brighter future for the next generation."
Current leadership at Sharsheret, including CEO Elana Silber, has frequently echoed these sentiments, noting that the organization’s mission has expanded to include not just those with cancer, but those at high risk. The "Sharsheret in the Kitchen" and "Sharsheret on Campus" initiatives represent a proactive shift toward wellness and early education, ensuring that the next generation is equipped with the knowledge Rochelle Shoretz had to fight to find.
Medical professionals have also lauded the organization’s role in the healthcare ecosystem. Dr. Elisa Port, Chief of Breast Surgery at Mount Sinai Health System, has previously noted that Sharsheret fills a "critical gap" that hospitals cannot—providing the cultural and emotional "glue" that keeps a patient whole during the rigors of clinical treatment.
Implications: The Future of Specialized Cancer Support
The success of Sharsheret and the Mirsky brothers’ 2025 appeal carries broader implications for the future of non-profit healthcare support.
1. The Model of Culturally Competent Care
Sharsheret has become a gold standard for "culturally competent care." By focusing on a specific demographic, they have been able to address nuances that broader organizations like the American Cancer Society might miss. This model is now being studied and replicated by other ethnic and religious groups looking to provide tailored support for their own communities.
2. The Shift from Treatment to Prevention
As genetic testing becomes more accessible, Sharsheret’s role is shifting. While they continue to support those in the midst of "the fight," a growing portion of their resources is dedicated to "previvors"—individuals who know they have a genetic predisposition but have not yet developed cancer. This proactive approach is likely to save thousands of lives in the coming decades.
3. The Sustainability of Founder-Led Organizations
The 10-year mark since Rochelle Shoretz’s death is a case study in organizational sustainability. Many non-profits falter after the loss of a charismatic founder. Sharsheret’s ability to not only survive but grow by tenfold suggests that its mission was deeply rooted in a genuine community need rather than just a single individual’s drive.
4. The Role of the "Next Generation"
The involvement of Shlomo and Dovid Mirsky signals a passing of the torch. Their appeal is a reminder that the impact of cancer is intergenerational. By framing the year-end donation as a way to "carry forward our mother’s legacy," they are engaging a younger demographic of donors who may not have known Rochelle personally but are living in the world she helped improve.
Conclusion: A Call to Action for 2025
As the Jewish community prepares for Chanukah, the "Festival of Lights," the Mirsky brothers’ message is one of hope amidst the memory of loss. The 2025 year-end campaign is more than a fundraising drive; it is a reaffirmation of a promise made 24 years ago in a suburban dining room.
For those looking to support the cause, donations can be made through the official portal at link.Sharsheret.org/EOY. As the organization looks toward 2026, the goal remains clear: to ensure that the "chain" of support remains unbroken, providing a lifeline for the next 275,000 people who will find themselves, as Rochelle Shoretz once did, looking for a hand to hold in the dark.
About the Author
